Physician profile
Stephen G Basheda
NPI 1811004609
$454,543.42
in general payments reported to CMS, 2019-2025
10 companies · $69K in 2025
The $69K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $28K · 2021: $51K · 2022: $54K · 2023: $131K · 2024: $99K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $285K · Food and Beverage: $6,933 · Travel and Lodging: $6,551 · Education: $94.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $284,544.01 |
| Food and Beverage | $6,933.11 |
| Travel and Lodging | $6,551.43 |
| Education | $94.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $276,588.43 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $143,521.90 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Mylan Specialty L.P. | $27,146.06 | 2019-2024 | Yupelri, Yupelri |
| Viatris Specialty LLC | $5,471.90 | 2025 | Yupelri |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Genentech USA, INC. | $61.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.18 | 2019-2025 | Jascayd, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $48.17 | 2025 | Arikayce |
| Verona Pharma, INC. | $38.59 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $16.40 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Basheda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.